CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 89 enrolled / 89 target
Drug / intervention
Certolizumab Pegoldrug
Likely dose
Certolizumab Pegol 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03020992
NCT03020992Phase 4CompletedMonitor (0.8/mo)Completion was 78mo ago
CompareCT.gov

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

UCB Biopharma SRL·interventional·Posted Jan 13, 2017·Updated Jun 23, 2026

In Brief

A Phase 4 clinical trial evaluating Certolizumab Pegol for Axial Spondyloarthritis (axSpA) and Anterior Uveitis (AU). Completed, enrolled 89 participants across 23 sites in 5 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis (axSpA), Anterior Uveitis (AU)
CountriesCzechia, Germany, Netherlands, Poland, Spain
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 13, 2017
Enrollment StartDec 21, 2016
Primary CompletionDec 4, 2019
Study CompletionJan 23, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.5 years ago

Arms & Interventions

Certolizumab Pegolexperimental

Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks

Drug: Certolizumab Pegol

Interventions

Certolizumab Pegoldrug

* pharmaceutical form: solution for infusion in prefilled syringe * concentration: 200 mg/mL * route of administration: subcutaneous